Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Open access

Abstract

KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly associated with poor prognosis and resistance to standard treatment. The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research. Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small molecules that covalently modify the mutated codon 12 cysteine is feasible. We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity. The PK/PD and efficacy of compound 13 will be highlighted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsmedchemlett.8b00382

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 2

  1. Bos J., 1989, Cancer Res., 49, 4682
  2. Jarvis L., 2016, C&EN, 94, 28

Cited by

See all 123

Metadata

Authors
Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., Chiang, H., Chicarelli, M. J., Davidson, K., Gaudino, J. J., Hallin, J., Hanson, L., Hee, K., Hicken, E. J., Hinklin, R. J., Marx, M. A., Mejia, M. J., Olson, P., Savechenkov, P., Sudhakar, N., Tang, T. P., Vigers, G. P., Zecca, H., & Christensen, J. G.
Affiliations
  • Array BioPharma (United States) (US)
  • Mirati Therapeutics (United States) (US)
Corresponding author
Fell, Jay B.
Venue
ACS Medicinal Chemistry Letters
Published
2018-11-07
Volume
9
Issue
12
Pages
1230-1234
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2900061002
Cited by
120
References
11
Citations by year
2026: 15 · 2025: 20 · 2024: 17 · 2023: 16 · 2022: 18 · 2021: 10 · 2020: 15 · 2019: 8 · 2018: 1
FWCI
3.11
Type
journal article
Language
en
Open access
Locations
  • ACS Medicinal Chemistry Letters (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Array BioPharma
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12C, irreversible covalent inhibitors, KRAS mutation, oncogene targeting, pharmacokinetics/pharmacodynamics, in vivo antitumor activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity. https://app.cochat.ai/papers/10.1021/acsmedchemlett.8b00382
The paper
Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., Chiang, H., Chicarelli, M. J., Davidson, K., Gaudino, J. J., Hallin, J., Hanson, L., Hee, K., Hicken, E. J., Hinklin, R. J., . . . Christensen, J. G. (2018). Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.8b00382

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.